Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Aethlon Medical (AEMD) EBIT Margin (2016 - 2023)

Aethlon Medical filings provide 13 years of EBIT Margin readings, the most recent being 431.51% for Q1 2023.

  • On a quarterly basis, EBIT Margin rose 2843170.0% to 431.51% in Q1 2023 year-over-year; TTM through Mar 2023 was 2072.12%, a 147041.0% increase, with the full-year FY2023 number at 2072.05%, up 147048.0% from a year prior.
  • EBIT Margin hit 431.51% in Q1 2023 for Aethlon Medical, up from 28863.21% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 211.97% in Q4 2019 to a low of 28863.21% in Q1 2022.
  • Median EBIT Margin over the past 5 years was 1590.14% (2021), compared with a mean of 5678.8%.
  • Biggest five-year swings in EBIT Margin: crashed -2224803bps in 2022 and later skyrocketed 2843170bps in 2023.
  • Aethlon Medical's EBIT Margin stood at 211.97% in 2019, then crashed by -85bps to 391.18% in 2020, then crashed by -3675bps to 14768.63% in 2021, then tumbled by -95bps to 28863.21% in 2022, then soared by 99bps to 431.51% in 2023.
  • The last three reported values for EBIT Margin were 431.51% (Q1 2023), 28863.21% (Q1 2022), and 14768.63% (Q4 2021) per Business Quant data.